EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Paradigm Shift in the Treatment of Chronic Obstructive Pulmonary Disease Improves Patient Outcomes

Yi-Jen Huang iD, Kwua-Yun Wang, Wu-Chien Chien iD, Chi-Hsiang Chung iD, Li-Ting Kao iD, Senyeong Kao, Chih-Feng Chian

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s511593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Yi-Jen Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, University of Kang Ning, Taipei, Taiwan. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Muscarinic Antagonists, Bronchodilator Agents, Adrenergic beta-2 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Tri-Service General Hospital (TSGHIRB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study evaluates the real-world impact of LAMA+LABA combination therapy on COPD outcomes, bridging the gap between experimental data and clinical practice. It aims to assess whether the paradigm shift in the treatment of chronic obstructive pulmonary disease has improved patient outcomes, particularly in terms of acute exacerbations, hospitalizations, and mortality, while providing insights to guide clinical and policy decisions. Patients and Methods: This retrospective study analyzes cohorts derived from outpatient and inpatient medical records from Taiwan's National Health Insurance Research Database. It includes individuals diagnosed with COPD in two periods: 2012-2014 and 2016-2018.

Results

The paradigm shift in COPD treatment has led to a significant transition in medication selection, moving away from single-agent or supplementary inhaled corticosteroid (ICS) regimens (from 99.61% to 20.99%) towards the use of dual bronchodilators or triple therapy (from 0.38% to 79.02%). The analysis between long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs) revealed no statistically significant differences in emergency department visits and hospitalizations. However, LABAs were associated with a notable reduction in all-cause mortality compared to LAMAs (aHR 0.674-0.765). Additionally, the widespread adoption of dual bronchodilator therapy and the implementation of precise guidelines for ICS use have led to significant reductions in emergency department visits (aHR 0.557-0.735), decreased hospitalizations (aHR 0.610-0.725), and improved mortality outcomes (aHR 0.226-0.294) among COPD patients.

Conclusion

The paradigm shift in treatment approaches has led to substantial improvements in patient outcomes for COPD, regardless of the treatment regimen employed. This development marks a significant advancement in enhancing both the efficacy and precision of COPD management. Why was this study done?: Chronic obstructive pulmonary disease (COPD) is a lung condition that makes breathing difficult. A treatment combining two inhaled medications, long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA), was approved in 2013 and shown to help in clinical trials. We wanted to see if it works as well in everyday healthcare settings. What did the researchers do and find?: Using a health database in Taiwan, we studied COPD patients treated with LAMA+LABA. The results showed fewer hospital visits and better symptom control, confirming the benefits seen in clinical trials. What do these results mean?: LAMA+LABA helps people with COPD in real-world settings, improving their quality of life. This supports its wider use as an effective treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveMuscarinic AntagonistsBronchodilator AgentsAdrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesLungPractice Patterns, Physicians'HumansRetrospective StudiesMaleFemaleAgedTreatment OutcomeMiddle AgedTaiwanDrug Therapy, CombinationHospitalizationDatabases, FactualTime FactorsDisease ProgressionAdministration, Inhalation

Stichwörter der Autor:innen

COPDacute exacerbationmortality

Substanzen

Muscarinic AntagonistsBronchodilator AgentsAdrenergic beta-2 Receptor AgonistsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Nursing, University of Kang Ning, Taipei, Taiwan.
  • School of Nursing, National Defense Medical Center, Taipei, Taiwan.
  • Nursing Department, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Rui Guang Healthcare Group, Taipei, Taiwan.
  • College of Nursing, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Medical Research, Tri-Service General Hospital, Taipei, Taiwan.

ORCID-Profile: Yi-Jen Huang, Wu-Chien Chien, Chi-Hsiang Chung, Li-Ting Kao

Förderung

  • Tri-Service General Hospital (TSGHIRB

Zitieren

APA

Huang, Y. J., Wang, K. Y., Chien, W. C., Chung, C. H., Kao, L. T., Kao, S., & Chian, C. F. (2025). Paradigm Shift in the Treatment of Chronic Obstructive Pulmonary Disease Improves Patient Outcomes. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s511593

Vancouver

Huang YJ, Wang KY, Chien WC, Chung CH, Kao LT, Kao S, et al. Paradigm Shift in the Treatment of Chronic Obstructive Pulmonary Disease Improves Patient Outcomes. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s511593

BibTeX
@article{Huang2025,
  author = {Huang, Yi-Jen and Wang, Kwua-Yun and Chien, Wu-Chien and Chung, Chi-Hsiang and Kao, Li-Ting and Kao, Senyeong and Chian, Chih-Feng},
  title = {Paradigm Shift in the Treatment of Chronic Obstructive Pulmonary Disease Improves Patient Outcomes},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s511593}
}
Kostenlos starten →